<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0003674'>Oxidative stress</z:mp> plays a central role in the pathogenesis and progression of late microangiopathic complications (diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo>) in <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies suggested that treatment of diabetic patients with the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> <z:chebi fb="0" ids="30314">alpha-lipoic acid</z:chebi> reduce <z:mp ids='MP_0003674'>oxidative stress</z:mp> and urinary albumin excretion </plain></SENT>
<SENT sid="2" pm="."><plain>In this prospective, open and non-randomized study, the effect of <z:chebi fb="0" ids="30314">alpha-lipoic acid</z:chebi> on the progression of endothelial cell damage and the course of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, as assessed by measurement of plasma thrombomodulin and urinary albumin concentration (UAC), was evaluated in 84 patients with <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> over 18 months </plain></SENT>
<SENT sid="3" pm="."><plain>Forty-nine patients (34 with Type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, 15 with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>) had no <z:chebi fb="11" ids="22586">antioxidant</z:chebi> treatment and served as a control group </plain></SENT>
<SENT sid="4" pm="."><plain>Thirty-five patients (20 with Type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, 15 with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>) were treated with 600 mg <z:chebi fb="0" ids="30314">alpha-lipoic acid</z:chebi> per day </plain></SENT>
<SENT sid="5" pm="."><plain>Only patients with an urinary albumin concentration &lt;200 mg/l were included into the study </plain></SENT>
<SENT sid="6" pm="."><plain>After 18 months of follow up, the plasma thrombomodulin level increased from 35.9+/-9.5 to 39.7+/-9.9 ng/ml (P&lt;0.05) in the control group </plain></SENT>
<SENT sid="7" pm="."><plain>In the <z:chebi fb="0" ids="30314">alpha-lipoic acid</z:chebi> treated group the plasma thrombomodulin level decreased from 37.5+/-16.2 to 30.9+/-14.5 ng/ml (P&lt;0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>The UAC increased in patients without <z:chebi fb="0" ids="30314">alpha-lipoic acid</z:chebi> treatment from 21.2+/-29.5 to 36.9+/-60.6 ng/l (P&lt;0.05), but was unchanged with <z:chebi fb="0" ids="30314">alpha-lipoic acid</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>It is postulated that the significant decrease in plasma thrombomodulin and failure of UAC to increase observed in the <z:chebi fb="0" ids="30314">alpha-lipoic acid</z:chebi> treated group is due to antioxidative effects of <z:chebi fb="0" ids="30314">alpha-lipoic acid</z:chebi>, and if so that <z:mp ids='MP_0003674'>oxidative stress</z:mp> plays a central role in the pathogenesis of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Furthermore, progression of the disease might be inhibited by <z:chebi fb="11" ids="22586">antioxidant</z:chebi> drugs </plain></SENT>
<SENT sid="11" pm="."><plain>A placebo-controlled study is needed </plain></SENT>
</text></document>